Autobacs Seven (9832) Fundamentals 2026 — P/E 14.2x, Revenue Analysis | SniperIQ
Autobacs Seven (9832) is a JP-listed Consumer Cyclical company in Specialty Retail with a market capitalization of ¥118.3B, trading at ¥1506.00 on the JPX. This SniperIQ fundamentals page covers Autobacs Seven's valuation (P/E 14.2x, P/B 0.9x), profitability (net margin 3.0%), revenue (¥280.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Autobacs Seven's market cap?
Autobacs Seven (9832) has a market capitalization of approximately ¥118.3B, trading at ¥1506.00 on the JPX. Market cap moves with the live share price.
What is Autobacs Seven's P/E ratio?
Autobacs Seven's trailing twelve-month P/E ratio is 14.2x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.
How profitable is Autobacs Seven?
Autobacs Seven runs a net profit margin of 3.0%, a gross margin of 35.8%, and an operating margin of 4.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Autobacs Seven generate?
Autobacs Seven reported revenue of ¥280.1B for fiscal year 2025, with net income of ¥8.4B and earnings per share (EPS) of 106.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Autobacs Seven pay a dividend?
Autobacs Seven offers a trailing dividend yield of about 4.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Autobacs Seven financially healthy?
Autobacs Seven carries a debt-to-equity ratio of 0.30x and a current ratio of 1.96x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Autobacs Seven a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Autobacs Seven (9832) the key facts are: market cap ¥118.3B, P/E 14.2x, revenue ¥280.1B, 52-week range 1431-1785. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.
Track Autobacs Seven's full fundamentals live
Get Autobacs Seven's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.